Back to User profile » Dr Sheng Liu
Papers published by Dr Sheng Liu:
Early Recurrent Hepatocellular Carcinoma with CK19 Positive Receiving Transarterial Chemoembolization After Surgical Resection: A Novel Risk Model Study
Zhu D, Yang W, Zhou HF, Liu S, Zhou WZ, Shao ZF, Shi HB, Feng Q
Journal of Hepatocellular Carcinoma 2026, 13:563631
Published Date: 27 February 2026
Increment of Skeletal Muscle Mass Predicts Survival Benefit for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors
Chen W, Yan HT, Zhang JX, Shen X, Liu J, Liu S, Shi HB, Ding Y, Zu QQ
Journal of Hepatocellular Carcinoma 2025, 12:415-426
Published Date: 27 February 2025
Prognosis of Patients with Hepatocellular Carcinoma Treated with TACE: A New Score Combining Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin
Lu SY, Sun HY, Zhou Y, Luo X, Liu S, Zhou WZ, Shi HB, Yang W, Tian W
Journal of Hepatocellular Carcinoma 2024, 11:1979-1992
Published Date: 22 October 2024
Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
Shen X, Zhang JX, Liu J, Liu S, Shi HB, Cheng Y, Zhang QQ, Yin GW, Zu QQ
Journal of Hepatocellular Carcinoma 2024, 11:1993-2003
Published Date: 21 October 2024
Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score–Matched Analysis
Chen YX, Zhang JX, Zhou CG, Liu J, Liu S, Shi HB, Zu QQ
Journal of Hepatocellular Carcinoma 2022, 9:685-694
Published Date: 1 August 2022
Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
Zhang JX, Chen P, Liu S, Zu QQ, Shi HB, Zhou CG
Journal of Hepatocellular Carcinoma 2022, 9:265-272
Published Date: 31 March 2022